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We recently characterized rimocidin B (3b) and
CE-108B (4b) as two polyene amides with improved
pharmacological properties, produced by genetically
modified Streptomyces diastaticus var. 108. In this
work,geneticandbiochemical analysisof theproducer
strain show that the two amides are derived from the
parental polyenes rimocidin (3a) and CE-108 (4a) by a
post-PKSmodificationof the free sidechain carboxylic
acid. This modification is mediated by an amidotrans-
ferase activity operating after the biosynthesis of
rimocidin (3a) and CE-108 (4a) are completed. Two
polyenes, intermediates of the biosynthetic pathway
of rimocidin (3a) and CE-108 (4a), were also isolated
and shown to have some improved pharmacological
properties compared with the final products.
Introduction
Polyenes are a large group of polyketides with antifun-
gal activities, and they include antibiotics such as am-
photericin B (1), pimaricin (2a), rimocidin (3a) (Figure
1), nystatin A1, and candicidin, all of which are biosyn-
thesized by multifunctional proteins known as Type I
modular polyketide synthases. The biological activity
of these compounds, and thus their pharmacological
properties, rely on the selectivity of their binding to
membrane-associated substituted sterols such as er-
gosterol or episterol (found in the fungal cytoplasmic
membrane or in some parasitic protozoa) [1–4]. As a re-
sult of these interactions, a multimolecular polyene/ste-
rol complex is formed, leading to impairment of plasma
membrane functions and, thus, cell death. Although
the affinity of the polyene macrolides for cholesterol-
containing membranes is low, it is not low enough to
avoid the toxic side effects of some of these drugs. In
spite of these limitations, amphotericin B (1) is still the
preferred clinical drug for treating systemic fungal
infections.
In order to gain insight into the structure/activity
relationship, many semisynthetic derivatives of ampho-
tericin B (1) were generated in the last decade [5–12].
*Correspondence: fmalpart@cnb.uam.esBoth the amino group of the sugar moiety and the
side chain carboxyl group were targeted, and their influ-
ence on the biological properties of this compound is
starting to be understood. Most of the semisynthetic
compounds were generated by molecular modeling of
amphotericin B (1), and this modeling was aimed at in-
creasing the selective toxicity for ergosterol-containing
membranes. Thus, amphotericin B (1), an efficient, old
antifungal drug, became a standard for the successful
generation of new analogs that had increased specific-
ity for their targets but retained pharmacokinetic prop-
erties at least equivalent to those of the parent
molecule. These findings make the macrolide polyenes
an attractive model by which to attempt to increase the
supply of lead compounds to fight serious fungal
diseases.
Recently, we isolated Streptomyces diastaticus var.
108 as a producer of two polyene macrolides, rimocidin
(3a) and CE-108 (4a) (Figure 1) [13]. A genetically modi-
fied derivative of this strain was shown to produce two
new, to our knowledge, polyene macrolides: rimocidin B
(3b) and CE-108B (4b) (Figure 1). In both compounds,
the free carboxyl group is substituted by an amide,
leading to compounds with lower toxicity, as indicated
by their low hemolytic activity and higher antifungal
properties [14]. Because of the importance of the novel
compounds as putative new leads, the biosynthetic
steps leading to this substitution were investigated in
more detail. At least two possible mechanisms were
suggested: (a) an amidotransferase acting as a tailoring
activity after the complete macrolactone rings were
generated; and (b) nondecarboxylating Claisen conden-
sation of malonamide during the growth of the polyke-
tide chain. It is noteworthy that the producer strain
can also synthesize oxytetracycline [13]; thus, malo-
namyl-CoA must be available as the starter unit for bio-
synthesis of this aromatic polyketide [15].
Insights into the biosynthetic mechanism, described
here, will be extremely useful in designing a strategy
for genetic engineering of S. diastaticus var. 108 and
perhaps other polyene producers in an attempt to ob-
tain new pharmaceuticals.
Results
Elucidation of the Biosynthetic Mechanism
for the Polyene Amides
To discriminate between the two possible mechanisms
for polyene amide formation, a genetic approach was
taken. Whatever the mechanism is, the role of the cyto-
chrome P450 monooxygenase RimG, claimed to be re-
sponsible for oxidation of the side chain methyl group
generated after condensation of methylmalonyl-CoA
units by module 7 [14], must be crucial. If an amido-
transferase activity is needed for amide formation, it
must presumably operate after the side chain methyl
group has been converted into the carboxyl group by
the rimG product; on the other hand, if the amide group
is incorporated by condensation of malonamyl-CoA
during chain assembly, the rimG gene would not be
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sence of polyene amides in the fermentation broth of
a rimG disruptant when a plasmid involved in the poly-
ene amide biosynthesis is cloned into it should indicate
the correct mechanism. We therefore attempted disrup-
tion of the rimG gene by insertional inactivation.
Because rimG lies within a long polycistronic tran-
script of 9 kbp, which also contains rimE, rimF, rimG,
rimH, and rimA [16] (Figure 2A), it was necessary to pre-
vent polar effects on genes located downstream of the
insertion point. The ermEP promoter, in the correct ori-
entation to drive transcription of the messenger RNA,
was therefore ligated upstream of the 582 bp SacII frag-
ment internal to the coding region of rimG (coordinates
8267–8849 bp of the sequence deposited under acces-
sion number AY442225). The resulting construct was
cloned in the PM1 phage vector in several steps de-
scribed in Table 1; the resulting recombinant phage,
PM1-768, carrying the desired construct was used to
infect S. diastaticus var. 108, giving rise to lysogens
S. diastaticus var. 108::PM1-768. Correct insertion into
the chromosome was confirmed by Southern blotting.
No tetraenes were detected in the fermentation broth
when several lysogens were analyzed by HPLC, sug-
gesting that low expression of the ermEP promoter
was responsible for the nonproducer phenotype. Unfor-
tunately, further attempts to disrupt rimG by using
a stronger promoter (ermEP*) were unsuccessful.
Two genes downstream of the insertion point could
be influenced by the polar effect: rimH (coding for a fer-
redoxin, presumably participating in the same oxidative
step as rimG) and rimA (coding for the PKS component
carrying the loading domain of rimocidin [3a] and CE-
108 [4a] (Figure 2A). Because the rimH product presum-
ably acts in concert with that of rimG, it is reasonable
that proper rimA expression would be the critical pa-
rameter for restoring formation of the polyene macro-
lides. In order to overcome this putative polar effect
and assure proper expression of the rimA gene, the
pSM743B plasmid (carrying an engineered rimA) was
used. This plasmid was previously shown to be func-
tional for both complementation of rimA disruption
and induction of polyene amide formation [14].
pSM743B was therefore transferred by intraspecific
Figure 1. Chemical Structures of Polyenes that Are Cited within the
Text
1, amphotericin B; 2a, pimaricin; 2b, AB-400; 3a, rimocidin; 3b, ri-
mocidin B; 3c, rimocidin C; 4a, CE-108; 4b, CE-108B; 4c, CE-108C.conjugation from the wild-type (S. diastaticus var. 108/
743B) to the rimG disruptant, giving S. diastaticus var.
108::PM1-768/743B. Correct integration of PM1-768
into the genome of S. diastaticus var. 108 and the pres-
ence of the plasmid pSM743B were confirmed
by Southern blotting and direct plasmid extraction,
respectively.
When the fermentation broth of S. diastaticus var.
108::PM1-768/743B was analyzed by HPLC, two major
compounds with the same spectrum and retention
time as those of rimocidin (3a) and CE-108 (4b) were
Figure 2. Disruption of rimG and rimE Genes
(A) Transcriptional organization of rimE, rimF, rimG, rimH, and rimA
in this chromosomal region [16]. The deduced transcripts are rep-
resented by thick, dotted arrows. The DNA fragments used for in-
sertional inactivation of the rimG and rimE genes are indicated by
gray lines below them; the numbers within brackets refer to the
DNA sequence deposited under accession number AY442225.
(B) HPLC analysis of the fermentation broth of Streptomyces dia-
staticus var. 108::PM1-768/743B. HPLC-MS analysis, carried out
under analytical conditions (see Experimental Procedures), sug-
gested for a and b the chemical structures corresponding to the
methylated intermediates of the biosynthetic pathway of CE-108
and rimocidin, respectively (CE-108C [4c] and rimocidin C [3c]). Be-
cause no polyene amides were detected, it can be concluded that
the side chain carboxylic group of the macrolactone ring is essen-
tial for polyene amide formation.
(C) HPLC analysis of the fermentation broth of the rimE disruptant.
Left: chromatographic profile (under analytical conditions, see Ex-
perimental Procedures) of fermentation broth from Streptomyces
diastaticus var. 108::PM1-702B/743B (see Table 1). Right: deduced
chemical structures for the corresponding aglycones: CE-108 agly-
cone (1), CE-108C aglycone (2), rimocidin aglycone (3), and rimoci-
din C aglycone (4). It is noteworthy that the absence of polyene
amides in the fermentation broth of this recombinant strain, in
which the glycosyltransferase RimE is not present, strongly sug-
gests that the native polyenes (CE-108 and rimocidin), but not their
aglycones, are the substrates for the amidotransferase activity.
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1095Table 1. Bacterial Strains and Vectors Used in This Study
Strain, Plasmid, or Phage Properties Reference
E. coli JM101 General cloning host [30]
Penicillium chrysogenum For antifungal activity assays ATCC10003
Candida albicans For antifungal activity assays ATCC10231
Candida krusei For antifungal activity assays ATCC14243
Aspergillus niger For antifungal activity assays ATCC1004
Cryptococcus neoformans For antifungal activity assays ATCC10226
S. lividans TK21 General cloning host [28]
S. diastaticus var. 108 Wild-type (WT), CE-108, and rimocidin producer [13]
S. diastaticus var. 108/KC859 WT derivative by integration of KC859 (WT, control) [16]
S. diastaticus var. 108/PM1-768 WT derivative with rimG disrupted by integration of PM1-768 This work
S. diastaticus var. 108::PM1-768/743B WT derivative with rimG disrupted by integration of PM1-768 and
transformed with pSM743B; rimocidin C and CE-108C producer
This work
S. diastaticus var. 108/PM1-702B WT derivative with rimE disrupted by integration of PM1-702B This work
S. diastaticus var. 108::PM1-702B/743B WT derivative with rimE disrupted by integration of PM1-702B and
transformed with pSM743B
This work
S. diastaticus var. 108/PM1-500 WT derivative with rimA disrupted by integration of PM1-500 [16]
S. diastaticus var. 108::PM1-500/784 WT derivative with rimA disrupted by integration of PM1-500 and
transformed with pSM784, tetraene nonproducer.
This work
pHJL401 Vector based on the SCP2* replicon and pUC19 replicon, tsr, 5.9 kb [31]
pEL-1 EcoRI-HindIII fragment from pIJ4090 corresponding to ermEP* [28]
cloned in the EcoRI-HindIII sites of pHJL401
This work
PM1 fC31att2 derivative, hyg, tsr [32]
pSM743B rimA under control of xylanase xysA promoter and ermE cloned into the
EcoRV site of pIJ922
[14]
pCNB5006 Vector pIJ2925 carrying the ermEP promoter [16]
pSM721 582-bp SacII internal fragment of rimG cloned into the HincII site of
pIJ2925
This work
pSM768 HindIII-XbaI fragment from pSM721, carrying the 582 bp SacII internal
fragment of rimG cloned into the BamHI-XbaI sites of pCNB5006
This work
PM1-768 1.0 kb BglII-PstI fragment from pSM768 cloned into the BamHI/PstI
sites of PM1
This work
pEL-1/702 0.8 kb SalI internal fragment of rimE cloned into the BamHI site of pEL-1 This work
PM1-702B 1.1 kb EcoRI-XbaI fragment from pEL-1/702 cloned into the Ecl136II site
of PM1
This work
Ap, ampicillin; tsr and hyg, thiostrepton and hygromycin resistance genes, respectively.detected: peaks a and b (Figure 2B). HPLC-MS analysis
showed that the deduced masses of peaks a and bwere
709 and 737, 30 units lower than for CE-108 (4a) and ri-
mocidin (3a). The mass differences are consistent with
the expected structures of the compounds generated
by rimG disruption: a methyl group at C-14 instead of
the carboxyl group of CE-108 (4a) and rimocidin (3a).
The two new, to our knowledge, tetraenes were named
CE-108C (4c) and rimocidin C (3c) for the lower and
higher retention time, respectively (Figure 1).
No polyene amides were detected in the fermentation
broth of the rimG disruptant, in which a plasmid respon-
sible for induction of polyene amides production in the
wild-type strain is present; this finding strongly sug-
gests that amide group formation takes place through
a tailoring amidotransferase activity on the free carboxyl
group rather than during assembly of the polyketide
chain. Thus, the substrates for the tailoring amidotrans-
ferase reaction would be CE-108 (4a) and rimocidin (3a)
and/or their respective aglycones.
rimE Gene Disruption
It remained unclear whether the substrates of the tailor-
ing activity were CE-108 (4a) and rimocidin (3a) or their
corresponding aglycones before glycosylation at C-17
with the mycosamine moiety.
In order to distinguish between these two possibili-
ties, another disruptant of rimE (encoding the glycosyl-
transferase [16]) was made. To prevent possible polareffects on downstream genes, the fragment for disrup-
tion was engineered with ermEP*, a stronger promoter
than the ermEP previously used [16]. The 0.8 kbp SalI
fragment internal to the coding region of rimE (coordi-
nates 5629–6484 bp of the sequence AY442225) was
first cloned into the pEL1 plasmid (Table 1) downstream
of the ermEP* promoter; and the ermEp* promoter and
the 0.8 kb SalI fragment (structurally similar to the pre-
vious construction with the ermEP promoter) were res-
cued and cloned into the PM1 vector. The resulting
recombinant phage (PM1-702B) (see Table 1) was
used to generate lysogens S. diastaticus var. 108/
PM1-702B; the expected insertion was confirmed by
Southern blotting. Fermentation broths from the lyso-
gens were analyzed by HPLC (Figure 2C), and all of
them showed the presence of four major peaks (1–4)
with spectra corresponding to typical tetraenes.
HPLC-MS analysis confirmed their masses. While peaks
1 and 3 showed the expected masses for the CE-108
(4a) and rimocidin (3a) aglycones, respectively, the
masses for peaks 2 and 4 were consistent with those
of the aglycones of CE-108 (4a) and rimocidin (3a),
which carry a methyl side chain instead of the carboxyl
group (see Figure 2C). These results were similar to
those described in other glycosyltransferase disrup-
tions [17]. No antifungal activity was detected for any
of these aglycones, as previously described. These re-
sults strongly support the idea that the low production
of these compounds in the former disruption was due
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1096Figure 3. HPLC Analysis of In Vitro Amido-
transferase Assays with Protein Extract from
Streptomyces diastaticus var. 108/784 and
Streptomyces sp. RGU5.3
(A–D) Assays with Streptomyces diastaticus
var. 108/784 are shown in (A)–(C), and assays
with Streptomyces sp. RGU5.3 are shown in
(D). Chromatograms in the left and right col-
umns show the products in the reaction mix-
ture at the start time (t 5 0) and after
incubation (t 5 60), respectively (times are
expressed in min). The peaks are: (a) CE-
108B (4b); (b), CE-108 (4a); (c), rimocidin B
(3b); (d), rimocidin (3a); (e), pimaricin (2a),
and (f), AB-400 (2b). (A) Enzymatic conver-
sion of CE-108 (peak b) into its amide deriv-
ative CE-108B (peak a). Peak a and the peak
marked with an asterisk at the start time are
CE-108B and rimocidin B, respectively, and
could not be completely removed in the pro-
tein extract. Note the increment of peak
a (right panel) as the product of an amido-
transferase activity. (B) Enzymatic conver-
sion of rimocidin (peak d) into its amide
derivative rimocidin B (peak c). Peak c and
the peak marked with an asterisk at the start
time are rimocidin B and CE-108B, respec-
tively, and they are present in the protein
extract. Similarly the product of the amido-
transferase activity (peak c) (right panel) is
significantly increased. (C) Enzymatic con-
version of pimaricin (e) into its amide deriva-
tive, AB-400 (peak f). The peak marked with an asterisk is rimocidin B, which remains in the protein extract. Note the relaxed specificity of the
amidotransferase from S. diastaticus var. 108/784 on the substrate recognition being able to convert a heterologous substrate (pimaricin) into
its corresponding amide (AB-400). (D) Enzymatic conversion of pimaricin (e) into its amide derivative, AB-400 (f). The left and right chromato-
grams show the compounds in the reaction mixture at the start time (t5 0) and after incubation time (t5 60); peak f is AB-400, which is present
in the protein extract, and e is pimaricin, which is added to the reaction mixture.to low expression from the promoter used rather than to
their chemical instability, as previously suggested [16].
Plasmid pSM743B (conferring the ability to produce
the polyene amides when introduced into the wild-
type strain [14]) was transferred by intraspecific conju-
gation into the rimE disruptant S. diastaticus var. 108/
PM1-702B. The desired recombinant was selected by
using the resistance markers and was confirmed by
Southern blotting and plasmid extraction. The fermen-
tation broth of the resultant strain (S. diastaticus var.
108::PM1-702B/743B) was subjected to HPLC-MS anal-
ysis, showing the same chromatographic profile as that
of S. diastaticus var. 108/PM1-702B without pSM743B.
The absence of polyene amides clearly suggests that
the amidotransferase activity requires previous incor-
poration of mycosamine at C-17.
In Vitro CE-108 and Rimocidin Amidation Asssays
From the results described above, the polyene amides
seem to be synthesized by a tailoring activity whose
substrates would be the native tetraenes CE-108 (4a)
and rimocidin (3a). In order to test for such activity in
the fermentation broth of the polyene amide producer,
S. diastaticus var. 108/784 (wild-type strain carrying
a plasmid that confers the ability to produce the polyene
amides [14]) was grown in SYM2 medium for 3 days.
After testing by HPLC for production of the polyene
amides, cell-free extracts were prepared as indicated
in the Experimental Procedures. To prevent interference
with the reaction products, most of the remainingpolyenes still present in this preparation were removed
by solid phase extraction with a Sep-Pak C18 cartridge
(Waters). A set of preliminary reactions was assayed for
polyene amide production in which several parameters
were tested: substrates, cofactors, amide donors, and
optimal pH (optimal amidotransferase activity was per-
formed as described in Experimental Procedures). The
reaction products were analyzed by HPLC. For a cleaner
enzyme preparation, the pellets from several ammonium
sulfate fractionations (25%, 45%, and 60% saturation)
were assayed for activity and were shown to be associ-
ated with the 60% pellet. A clear conversion of both
CE-108 (4a) and rimocidin (3a) was detected (Figures
3A and 3B). The identity of these peaks was confirmed
by HPLC-MS analysis. No polyene amides were de-
tected when ATP was absent from the enzyme reaction,
suggesting that the amidotransferase activity is indeed
an ATP-dependent reaction.
In Vitro Heterologous Amidation Asssay
To deduce the specificity of the polyene amidotranfer-
ase activity, pimaricin (2a) (Figure 1) and amphotericin
B (1), along with CE-108 (4a) and rimocidin (3a) as con-
trol, were used as substrates in the amidotransferase
reaction. The cell-free extracts and the reactions were
performed as described in Experimental Procedures.
As shown in Figure 3C, a protein extract from S. diasta-
ticus var. 108/784 could also convert pimaricin (2a) into
its corresponding amide, AB-400 (2b) (Figure 1) [18].
No conversion of amphotericin B (1) was detected,
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cus var. 108 does not recognize 1 as a substrate under
our experimental conditions. Cell-free extracts from
Streptomyces RGU5.3 (recently characterized in our
laboratory as producers of AB-400 [14]) were also tested
for amidotransferase activity. In this strain, pimaricin (2a),
not rimocidin (3a), CE-108 (4a), nor amphotericin B (1),
could be converted into its corresponding amide under
our experimental conditions, suggesting that this activity
is more specific in substrate recognition than that of
S. diastaticus var. 108 (see Figure 3D).
Characterization of Rimocidin C and CE-108C
Chemical Structure Elucidation
In order to verify the chemical structures of CE-108C
(4c) and rimocidin C (3c), they were purified from the fer-
mentation broth of S. diastaticus var. 108::PM1-768/
743B by using a C8 reverse phase silica gel (see Exper-
imental Procedures).
Compound 3c was obtained as a yellow powder,
which afforded pseudomolecular ions at m/z 738
([M1H]1) and 760 ([M1Na]1) by (1)2ESI MS, according
to the molecular formula C39H63NO12 (by high-resolution
MS found 738.442217, calcd. 738.442300 for [M1H]1).
Compared with the formula of 3a (C39H61NO14), this
corresponds to the loss of two oxygen atoms and the
addition of two protons in 3c, which can formally be in-
terpreted as an exchange of the carboxy group at C-14
against a methyl residue.
The 1H NMR spectrum was very similar to that of ri-
mocidin (3a) and displayed three signals in the sp2
range, i.e., a doublet-of-doublet (dd) at d 6.30, a multiplet
at d 6.05–6.18, and a second dd at d 5.90 (Table 2). The
protons of the sugar moiety appeared in the range of
d 3.25–4.62. The aliphatic region of the 1H NMR spec-
trum also exhibited similarities with that of 3a, especially
with respect to five complex multiplet patterns in the
range of d1.30–2.50. Four methyl groups instead of
three, as in 3a, appeared as two triplets and two dou-
blets at d 0.90, 0.95 and 1.26, 1.00, respectively. The ma-
jor difference between 3a and 3c was the presence of
the methyl doublet at d1.00, which showed an H,H
crosssignal in the COSY spectrum with the 14-H at
d 1.22 (dC43.8).
The 13C NMR spectrum indicated 39 carbon signals
as in 3a and as demanded by the molecular formula.
This and the similarity of the proton spectra permitted
the conclusion that 3a and 3c possess the same carbon
skeleton, including the amino sugar, the only difference
being the presence of only two carbonyl groups instead
of three as in 3a. The signals at d 211.6 and 174.5 were
attributed to a ketone and a lactone carbonyl, respec-
tively. The HMBC 3J coupling of the proton at d 5.03
(C-27) to the carbonyl at 174.5 confirmed the lactone;
thus, rimocidin C must be 14-decarboxy-14-methyl-
rimocidin (3c).
The yellow powdery 4c was readily soluble in metha-
nol. Here too, the 1H NMR spectrum exhibited similari-
ties with those of 3c and 4a (Table 3; values from [13]),
mainly in the aromatic and sugar region. The aliphatic
region displayed the signals of four methyl groups as
well—three doublets at d 1.25, 1.23, and 0.99 and a trip-
let at 0.90—instead of three methyl signals as in 4a. The
(1)2ESI mass spectrum determined the molecularweight of 4c as m/z 709, and high resolution delivered
the molecular formula C37H59NO12 (found 710.410905,
calcd. 710.411000 for [M1H]1). The 13C NMR spectrum
confirmed the presence of 37 carbon signals as in 4a
and as demanded by the molecular formula. Compari-
son with that of CE-108B (4b) revealed the presence
of only two carbonyl signals at d211.3 and 174.3, attrib-
uted again to a ketone and lactone carbonyl. The major
difference here was the absence of the acid carbonyl,
which appeared at d 179.3 in 4a, and the presence of
an additional methyl signal at 13.7 that belongs to the
methyl doublet at d 0.99 in the 1H NMR spectrum.
A careful comparison of the data of 4a and 4c (Table 3)
indicated clearly that, also in this tetraene, the C-14
carboxy group of 4a was replaced by a methyl group,
which identified CE-108C as the 14-decarboxy-methyl
derivate 4a.
Biological Activities of Rimocidin C and CE-108C
Antifungal activity of the noncarboxylated tetraenes
rimocidin C (3c) and CE-108C (4c) was tested against
Table 2. 1H NMR and 13C NMR Data of Rimocidin C in [D4]Methanol
Position 1H (Int., mult., J [Hz]) 13C
1 — 174.5
2 2.18 (1H, dt, 10.8, 3.6) 57.8
3 4.07 (1H, dd, 9.5, 2.4) 69.2
4 2.40; 2.46 (2H, m) 49.1
5 — 211.6
6 2.46; 2.30 (2H, m) 45.6
7 1.39 (2H, m) 19.5
8 1.30; 1.40 (2H, m) 38.3
9 3.80 (1H, m) 70.3
10 1.60 (2H, m) 48.8
11 — 98.7
12 1.96 (1H, dd, 4.6, 12.2), 1.26 (1H, m) 45.8
13 3.30a (1H, m) 71.8
14 1.22 (1H, m) 43.8
14-Me 1.00 (3H, d, 6.3) 13.7
15 3.91 (1H, tbr, 9.1) 71.3
16 2.20; 1.70 (2H, m) 38.6
17 4.42 (1H, tbr, 6.4) 78.7
18 5.90 (1H, dd, 15.2, 8.3) 137.4
19 6.30 (1H, dd, 14.5, 10.7) 134.4
20 6.11 (1H, m) 130.9*
21 6.11 (1H, m) 134.6*
22 6.11 (1H, m) 133.5*
23 6.11 (1H, m) 133.3*
24 6.11 (1H, m) 133.3*
25 5.60 (1H, m) 132.1
26 2.30; 2.50 (2H, m) 39.3
27 5.01 (1H, m) 74.8
28 1.62 (2H, d, 6.3) 38.1
29 1.40; 1.60 (2H, m) 20.5
30 0.95 (3H, d, 7.4) 14.2
1$ 1.60; 1.90 (2H, m) 23.9
2$ 0.90 (3H, t, 7.5) 12.3
Sugar Part
1# 4.57 (1H, s) 99.5
2# 4.04 (1H, d, 2.3) 69.5
3#b 2.80 (1H, m) 57.4
4#b 3.58 (1H, m) 70.3
5#b 3.23 (1H, m) 74.6
6# 1.26 (3H, d, 5.5) 17.9
1H NMR data of rimocidin C (3c) were collected at 600 MHz, and 13C
NMR data were collected at 150.8 MHz.
a Signals are partially overlapped by solvent.
b Tentatively assigned.
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Position 4a, 1H, 500 MHz 4a, 13C, 125.7 MHz 4c, 1H, 600 MHz 4c, 13C, 150.8 MHz
1 — 173.4 — 174.3
2 2.18 (1H, dt, 9.6, 3.8) 56.3 2.15 (1H, dt, 10.5, 3.7) 57.4
2$ 1.59, 1.90 (2H, dq, 7.5, 3.8) 22.4 1.90, 1.59 (2H, 2 m) 21.0
2$-Me 0.92 (3H, t, 7.5) 10.9 0.90 (3H, t, 7.4) 12.0
3 4.11 (1H, dd, 9.6, 2.2) 68.5 4.07 (1H, dd, 10.6, 2.2) 69.4
4 2.37, 2.46 (2H, m) 48.8 2.44, 2.32 (2H, 2 m) 47.6
5 — 210.6 — 211.3
6 2.46, 2.32 (2H, m) 44.3 2.44, 2.32 (2H, 2 m) 45.2
7 1.39, 1.61 (2H, m) 19.6 1.38, 1.56 (2H, 2 m) 20.7
8 1.39, 1.30–1.26 (2H, m) 37.6 1.40–1.20 (2H, m) 38.3
9 4.12 (1H, ddt, 9.3, 8.2, 2.2) 68.4 3.56 (1H, ddd, 14.7, 10.8, 4.6) 70.1
10 1.61 (2H, m) 46.5 1.56 (2H, m) 45.8
11 — 97.8 — 98.7
12 2.02, 1.30–1.26 (2H, m) 44.1 1.96, 1.30–1.26 (2H, 2 m) 43.7
13 4.29 (1H, ddd, 11.1, 10.5, 4.6) 66.9 3.89 (1H, tbr, 9.1) 69.3
14 2.03 (1H, t, 9.3) 60.5 1.24 (1H, m) 38.6
14-COOH — 179.3 — —
14-Me — — 0.99 (3H, 6.3) 13.7
15 4.37 (1H, dd, 9.3, 8.2) 66.6 4.36 (1H, m) 69.4
16 2.30, 1.70 (2H, dd, 8.2) 38.7 2.32, 1.72 (2H, 2 m) 38.6
17 4.45 (1H, td, 3.5, 8.3) 78.2 3.83 (1H, m) 78.7
18 5.95 (1H, dd, 15.3, 8.3) 136.0 5.90 (1H, dd, 15.2, 8.3) 137.5
19 6.35 (1H, dd, 13.8, 10.7) 133.6 6.28 (1H, dd, 13.2, 10.8) 134.6
20 6.13 (1H, m) 129.3a 6.08 (1H, m) 130.7
21 6.13 (1H, m) 133.4a 6.08 (1H, m) 134.3
22 6.13 (1H, m) 132.3a 6.08 (1H, m) 133.5
23 6.13 (1H, m) 132.3a 6.08 (1H, m) 133.4
24 6.13 (1H, m) 132.6a 6.08 (1H, m) 133.3
25 5.63 (1H, ddd, 14.0, 9.5, 5.1) 131.1 5.61 (1H, m) 132.1
26 2.32, 2.40 (2H, m) 40.0 2.45, 2.30 (2H, 2 m) 40.9
27 5.07 (1H, ddq, 10.5, 6.3, 1.9) 70.8 5.04 (1H, ddq, 10.2, 6.3, 1.9) 71.8
28 1.26 (3H, d, 6.3) 20.0 1.23 (3H, d, 6.3) 20.4
Sugar
1# 4.62 (1H, s) 98.2 4.51 (1H, sbr) 99.5
2# 4.03 (1H, d, 2.8) 68.0 4.05 (1H, d, 2.1) 70.3
3# 3.20 (1H, dd, 9.0, 2.8) 56.1 3.21 (1H, m) 57.4
4# 3.37b (1H, m) 69.5 3.26 (1H, m) 71.4
5# 3.35b (1H, m) 73.5 3.30b (1H, m) 74.6
6# 1.31 (3H, d, 5.7) 16.7 1.25 (3H, d, 5.9) 17.9
Signal intensity, multiplicity, and coupling constants are listed in brackets. The signals of 4c were assigned tentatively according to the literature
values of 4a. See [13] for the 1H and 13C NMR data of CE-108.
a Tentatively assigned.
b The signal is partially overlapped by solvent.several fungi—Penicillium chrysogenum, Candida albi-
cans, Aspergillus niger, Candida krusei, and Cryptococ-
cus neoformans—as previously described [14] and was
compared with that of the native tetraenes. The
antifungal activities of the two intermediate tetraenes,
rimocidin C (3c) and CE-108C (4c), were not significantly
different from those of their final products (data not
shown).
To test whether or not other pharmacological proper-
ties of these tetraenes were different, hemolytic activity
assays were also performed and compared with the pa-
rental compounds. Human erythrocytes were used for
these assays; the results are shown in Table 4. It is note-
worthy that, although the antifungal activities of 3a and
3c were similar, their toxicity (measured in terms of he-
molytic activity) was 2.5- to 5-fold lower for rimocidin C
(3c) than the parental rimocidin (3a). Up to 600 nanomols
of CE-108C (4c) were used for the hemolytic assays; the
detected hemolysis was less than 20% (data not
shown), suggesting a much lower toxicity of the non-
carboxylated CE-108 (4c) than for any of the othercoproduced metabolites. This suggests an interesting
improvement in biological properties.
Discussion
The polyene macrolides are a large group of com-
pounds with interesting pharmacological properties, in-
cluding potent antifungal activity, a broad antifungal
spectrum, low probability of inducing resistance in the
target strains, and a mechanism of action. These posi-
tive properties need to be set against negative ones
such as high toxicity to mammals and very low water
solubility. Because of the properties of some of these
compounds, many approaches have been taken to gen-
erate new drugs: semisynthetic derivatives with more
specific antifungal effects and higher water solubility
[1, 6, 7, 10, 19], and genetic manipulation of biosynthetic
genes [17, 20–22]. These two approaches face similar
challenges: to increase the repertoire of these interest-
ing compounds and improve the pharmacological prop-
erties of preexisting compounds as antifungal leads.
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generating new pharmaceuticals.
In a previous report, we described two polyene com-
pounds, rimocidin B (3b) and CE-108B (4b), produced
by genetically modified Streptomyces diastaticus var.
108 [14]. Here, we show that these polyenes are derived
from the parental compounds, rimocidin (3a) and CE-
108 (4a), through modification by a tailoring ATP-depen-
dent amidotransferase activity that converts the free
carboxyl group into an amide group. Both polyenes,
but not their aglycones, are substrates for such biocon-
version. Under our experimental conditions, the enzyme
system can also recognize the closely related polyene
pimaricin (2a), but not amphotericin B (1). Although 2a
and 3a are both tetraenes, their aglycones differ sub-
stantially: 3a lacks the epoxy group of pimaricin (2a),
and the C2 and C3 alkyl groups of 3a are not present
in 2a. In contrast to the successful conversion by ex-
tracts of S. diastaticus var. 108/784, extracts of Strepto-
myces sp. RGU5.3, producer of AB-400 (2b, pimaricin
amide) [14], did not catalyze the conversion.
The relaxed specificity in substrate recognition by the
enzyme from S. diastaticus var. 108 is promising. We do
not yet have enough experimental evidence to deter-
mine if the size of the macrolactone ring plays a critical
role in substrate recognition. Therefore, the possibility
of a successful enzymatic conversion of amphotericin
B (1) into its amide derivative under different experimen-
tal procedures cannot be ruled out. More experimental
work and/or eventually a properly engineered protein
would be needed to gain insight into the critical param-
eters. Attempts are in progress to isolate the S. diasta-
ticus var. 108 gene for amidotransferase activity. The
possibility that this activity, properly engineered, could
modify other polyenes is an exciting challenge for the
near future; tools based on combinatorial biosynthesis
will provide interesting opportunities for generating
new polyene compounds with improved pharmacologi-
cal properties by genetic engineering.
Based on sequence similarity with other monooxyge-
nases such as PimG, NysN, and AmphN [23], we
Table 4. Comparative Hemolytic Activity of Rimocidin,
3a; Rimocidin C, 3c; and CE-108, 4a
















The values tested for each tetraene are given in nanomols (left
column), and the corresponding hemolytic activities are expressed
as a percentage of total hemolysis. All of the values are the average
of three independent assays.previously proposed that rimG would encode a cyto-
chrome P450 monooxygenase involved in the conver-
sion of the side chain methyl group of the
macrolactone ring of 3a and CE-108 (4a) into the free
carboxylic acid [16]. Our experimental results confirm
this prediction and confirm that the products accumu-
lated by the rimG disruptants are rimocidin C (3c) and
CE-108C (4c), the corresponding methylated polyene
precursors, based on the finding that the C-14 methyl
is not oxidized to the carboxyl group. The tetraene pro-
duction profile observed in the rimG disruptant sug-
gests that the carboxyl group is not required for
attachment of mycosamine to the aglycone moiety
and that the methylated CE-108 (4c) and rimocidin (3c)
aglycones can also be substrates for transglycosyla-
tion. From the results of rimE and rimG disruption, we
cannot establish the relative order in which those tailor-
ing gene products (RimG and RimE) operate; a feedback
inhibition of post-PKS tailoring steps as suggested by
Chen et al. [17] cannot be excluded.
Despite the fact that the carboxyl group is highly con-
served among polyenes, we provide evidence that this
group is not essential for the biological activity of rimo-
cidin and CE-108; moreover, its absence led to poly-
enes with lower toxicity compared with their oxidized
counterparts. It is noteworthy that attempts to disrupt
the corresponding monooxygenase gene in other poly-
ene producers failed [24, 25]; there was no clear expla-
nation. Nevertheless, the successful generation of the
amphN mutant by means of an in frame deletion of the
gene [26] has been recently reported and results in non-
carboxylated amphotericin derivatives with similar bio-
logical properties as those described in this work.
These findings create the exciting possibility that these
intermediates may not be toxic for other producers as
had been suggested [25]. Thus, the improved properties
shown by these methyl-derived polyenes could also be
shared by other polyenes. A targeted disruption of sim-
ilar cytochrome P450 monooxygenase genes in other
polyene biosynthetic clusters would provide an alterna-
tive way to generate new pharmaceutical leads.
To our knowledge, the tailoring activity described in
this work is the first example of an enzyme involved in
an in vivo chemical modification of the free carboxyl
group of two typical polyenes into an amide group,
a substitution that clearly increases selective toxicity
toward ergosterol-containing membranes (more anti-
fungal activity). Nevertheless, some other toxic effects
unrelated to the membranes cannot be ruled out, and
more work would be needed to test such possibility.
Significance
This work describes an amidotransferase activity in-
volved in chemical modification of the free carboxyl
group of two typical macrolide polyenes into an amide
group, leading to improved pharmaceuticals. The re-
laxed specificity of this enzymatic activity, being
able to modify pimaricin as well as CE-108 and rimoci-
din in vitro, creates the possibility of extending this
modification in vivo to other polyene producers in
an attempt to generate improved antifungal drugs.
Disruption of rimG, encoding a P450 monooxygenase
involved in free carboxyl group formation of rimocidin
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noncarboxylated tetraenes with lower toxicity toward
cholesterol-containing membranes. This finding cre-
ates the exciting possibility of obtaining other non-
carboxylated polyenes with better pharmacological
properties by disrupting a gene with a similar function
in other polyene biosynthetic pathways.
Experimental Procedures
Bacterial Strains, Cloning Vectors, and Growth Conditions
The bacterial strains and plasmids are described in Table 1. Strep-
tomyces diastaticus var. 108 and its derivatives were cultured in
SYM2 medium [27]. Streptomyces lividans TK21 [28] was used for
propagation of phages and as a cloning host. E. coli JM101 was
grown on Luria-Bertani (LB) agar or in LB broth [29]. Penicillium
chrysogenum ATCC10003 was used for testing antifungal activity
and was grown in MPDA medium as previously described [16].
Genetic Procedures
E. coli JM101 was grown and transformed as described elsewhere
[29]. Streptomyces strains were manipulated as described else-
where [28]. Intraspecific conjugation was carried out as described
previously [14]. DNA manipulations were performed as described
by Maniatis et al [29].
Assay for Tetraenes Production under Analytical Conditions
The tetraene production assays were performed as previously de-
scribed [16]. HPLC analyses for analytical purposes were carried
out in all cases as described elsewhere [13].
HPLC-MS Assays
The mass spectra were determined on an 1100MSD HPLC
connected to a quadrupole Agilent Technology Detector, by using
electrospray as a source and a positive ionization mode. The chro-
matographic conditions were the same as those described above.
NMR Measurements
NMR spectra were measured on a Varian Inova 600 (599.740 MHz)
spectrometer. ESI mass spectra were recorded on a Finnigan
LCQ with quaternary pump Rheos 4000 (Flux Instrument). HR ESI
mass spectra were measured on a Bruker FTICR 4.7 T mass
spectrometer.
Purification of CE-108C and Rimocidin C
Streptomyces diastaticus var. 108::PM1-768/743B was grown on
solid SYM2 medium supplemented with thiostrepton (50 mg/ml)
and erythromycin (25 mg/ml) for selection of chromosomal insertion
and plasmid markers, respectively. After 6 days, all of the solid me-
dium was fragmented and processed as described previously [14].
CE-108C (4c) and rimocidin C (3c) were purified by HPLC by using
a semipreparative column (Supelcosil PLC-8, 250 3 21.2 mm); the
applied gradient was similar to that previously described for analyt-
ical fractionation [14] and was controlled with a Waters Automated
Gradient Controller. The purified compounds were pooled and sub-
jected to an additional desalting step with Sep-Pak C18 (Waters)
cartridges and were finally freeze dried twice.
Hemolytic Activity Assay
The assays were carried out on human blood erythrocytes enriched
as previously described [14].
Cell-free Extract Preparation and In Vitro Amidation Assays
Cell-free extracts were prepared from Streptomyces diastaticus var.
108/784 and Streptomyces sp. RGU5.3. The strains were grown in
50 ml SYM2 medium for 3 days. The mycelium was collected by cen-
trifugation at 5,0003 g at 4ºC for 10 min, washed with 20% glycerol,
and finally resuspended in 15 ml 20% glycerol. Aliquots of 500 ml
were stored at 220ºC until use. When needed, the cells were pel-
leted by centrifugation and resuspended in 50 mM Tris-HCl (pH
7.5), 0.5 mM EDTA, 5% glycerol, 50 mM NaCl, 0.5 mM PMSF, and
1 mM b-mercaptoethanol (TEPM buffer). The cells were disrupted
by sonication and centrifuged at 4,000 3 g for 15 min at 4ºC, andthe supernatant was again centrifuged. The polyenes contaminating
the final supernatant were partially removed by passing the samples
through Sep-Pak C18 (Waters) cartridges. The extracts were sub-
jected to ammonium sulfate fractionation and raised sequentially
to 45% and 60% ammonium sulfate saturation; the pellets were col-
lected at 30,000 3 g at 4ºC for 10 min and dissolved at 4-fold con-
centration in TEPM buffer. The pellet obtained at 60% ammonium
sulfate saturation was used for the amidotransferase assays.
The amidotransferase assays were performed in 200 ml reaction
containing 100 ml protein extract obtained as described above,
4 3 106 Units of Optical Density measured at 340 nm of the corre-
sponding polyenes, 2.5 mM glutamine, 25 mM NaCl, 10 mM
MgCl2, 4 mM ATP, and 125 mM TES buffer (pH 7.2). The reactions
were incubated at 30ºC for 60 min, were stopped by the addition
of 1 volume of methanol, and were clarified by centrifugation at
4,000 3 g, and the products were analyzed by HPLC. Rimocidin
and CE-108, which were used as substrates for these reactions,
were purified as previously described [14]; pimaricin and amphoter-
icin B were purchased from Calbiochem (catalog nos. 527962 and
171375, respectively).
Acknowledgments
This work was supported by grants to F.M. from the Spanish Minis-
tero de Ciencia y Tecnologı´a BIO2002-01445. We thank Sir Prof.
D.A. Hopwood for critically reading the manuscript.
Received: July 8, 2005
Revised: August 4, 2005
Accepted: August 8, 2005
Published: October 21, 2005
References
1. Baginski, M., Resat, H., and Borowski, E. (2002). Comparative
molecular dynamics simulations of amphotericin B-cholesterol/
ergosterol membrane channels. Biochim. Biophys. Acta 1567,
63–78.
2. Cohen, B.E. (1998). Amphotericin B toxicity and lethality: a tale
of two channels. Int. J. Pharm. 162, 95–106.
3. Cohen, B.E., Ramos, H., Gamargo, M., and Urbina, J. (1986). The
water and ionic permeability induced by polyene antibiotics
across plasma membrane vesicles from Leishmania sp. Bio-
chim. Biophys. Acta 860, 57–65.
4. Saha, A.K., Mukherjee, T., and Bhaduri, A. (1986). Mechanism of
action of amphotericin B on Leishmania donovani promasti-
gotes. Mol. Biochem. Parasitol. 19, 195–200.
5. Adjou, K.T., Demaimay, R., Deslys, J.P., Lasmezas, C.I.,
Beringue, V., Demart, S., Lamoury, F., Seman, M., and
Dormont, D. (1999). MS-8209, a water-soluble amphotericin B
derivative, affects both scrapie agent replication and PrPres
accumulation in Syrian hamster scrapie. J. Gen. Virol. 80,
1079–1085.
6. Che´ron, M., Cybulska, B., Mazerski, J., Grzybowska, J.,
Czerwinski, A., and Borowski, E. (1988). Quantitative structure-
activity relationships in amphotericin B derivatives. Biochem.
Pharmacol. 37, 827–836.
7. Cybulska, B., Bolard, J., Seksek, O., Czerwinski, A., and
Borowski, E. (1995). Identification of the structural elements of
amphotericin B and other polyene macrolide antibiotics of the
hepteane group influencing the ionic selectivity of the perme-
ability pathways formed in the red cell membrane. Biochim.
Biophys. Acta 1240, 167–178.
8. Cybulska, B., Gadomska, I., Mazerski, J., Borowski, J.G.E.,
Cheron, M., and Bolard, J. (2000). N-Methyl-N-D-fructosyl am-
photericin B methyl ester (MF-AME), a novel antifungal agent
of low toxicity: monomer/micelle control over selective toxicity.
Acta Biochim. Pol. 47, 121–131.
9. Graybill, J.R., Najvar, L.K., Fothergill, A., Hardin, T., Rinaldi, M.,
Lambros, C., and Regen, S.L. (1998). KY-62, a polyene analog
of amphotericin B, for treatment of murine candidiasis. Antimi-
crob. Agents Chemother. 42, 147–150.
10. Mazerski, J., Bolard, J., and Borowski, E. (1995). Effect of the
modifications of ionizable groups of amphotericin B on its ability
Polyene Amides Biosynthesis
1101to form complexes with sterols in hydroalcoholic media. Bio-
chim. Biophys. Acta 1236, 170–176.
11. Parmegiani, R.M., Loebenberg, D., Antonacci, B., Yarosh-
Tomaine, T., Scupp, R., Wright, J.J., Chiu, P.J., and
Miller, G.H. (1987). Comparative in vitro and in vivo evaluation
of N-D-ornithyl amphotericin B methyl ester, amphotericin B
methyl ester, and amphotericin B. Antimicrob. Agents Chemo-
ther. 31, 1756–1760.
12. Szlinder-Richert, J., Mazerski, J., Cybulska, B., Grzybowska, J.,
and Borowski, E. (2001). MFAME, N-methyl-N-D-fructosyl am-
photericin B methyl ester, a new amphotericin B derivative of
low toxicity: relationship between self-association and effects
on red blood cells. Biochim. Biophys. Acta 1528, 15–24.
13. Pe´rez-Zu´n˜iga, F.J., Seco, E.M., Cuesta, T., Degenhardt, F.,
Rohr, J., Vallı´n, C., Iznaga, Y., Pe´rez, M.E., Gonza´lez, L., and
Malpartida, F. (2004). CE-108, a new macrolide tetraene anti-
biotic. J. Antibiot. (Tokyo) 57, 197–204.
14. Seco, E.M., Cuesta, T., Fotso, S., Laatsch, H., and Malpartida, F.
(2005). Two polyene amides produced by genetically modified
Streptomyces diastaticus var. 108. Chem. Biol. 12, 535–543.
15. Petkovic, H., Thamchaipenet, A., Zhou, L.H., Hranueli, D.,
Raspor, P., Waterman, P.G., and Hunter, I.S. (1999). Disruption
of an aromatase/cyclase from the oxytetracycline gene cluster
of Streptomyces rimosus results in production of novel polyke-
tides with shorter chain lengths. J. Biol. Chem. 274, 32829–
32834.
16. Seco, E.M., Pe´rez-Zun˜iga, F.J., Rolo´n, M.S., and Malpartida, F.
(2004). Starter unit choice determines the production of two tet-
raene macrolides, rimocidin and CE-108, in Streptomyces
diastaticus var. 108. Chem. Biol. 11, 357–366.
17. Chen, S., Huang, X., Zhou, X., Bai, L., He, J., Jeong, K.J.,
Lee, S.Y., and Deng, Z. (2003). Organizational and mutational
analysis of a complete FR-008/candicidin gene cluster encoding
a structurally related polyene complex. Chem. Biol. 10, 1065–
1076.
18. Can˜edo, L.M., Costa, L., Criado, L.M., Ferna´ndez Puentes, J.L.,
and Moreno, M.A. (2000). AB-400, a new tetraene macrolide iso-
lated from Streptomyces costae. J. Antibiot. (Tokyo) 53, 623–
626.
19. Borowski, E. (2000). Novel approaches in the rational design of
antifungal agents of low toxicity. Farmaco 55, 206–208.
20. Brautaset, T., Bruheim, P., Sletta, H., Hagen, L., Ellingsen, T.E.,
Strom, A.R., Valla, S., and Zotchev, S.B. (2002). Hexaene deriv-
atives of nystatin produced as a result of an induced rearrange-
ment within the nysC polyketide synthase gene in S. noursei
ATCC 11455. Chem. Biol. 9, 367–373.
21. Byrne, B., Carmody, M., Gibson, E., Rawlings, B., and Caffrey, P.
(2003). Biosynthesis of deoxyamphotericins and deoxyampho-
teronolides by engineered strains of Streptomyces nodosus.
Chem. Biol. 10, 1215–1224.
22. Mendes, M.V., Recio, E., Fouces, R., Luiten, R., Martin, J.F., and
Aparicio, J.F. (2001). Engineered biosynthesis of novel polyenes:
a pimaricin derivative produced by targeted gene disruption in
Streptomyces natalensis. Chem. Biol. 8, 635–644.
23. Aparicio, J.F., Caffrey, P., Gil, J.A., and Zotchev, S.B. (2003).
Polyene antibiotic biosynthesis gene clusters. Appl. Microbiol.
Biotechnol. 61, 179–188.
24. Caffrey, P., Lynch, S., Flood, E., Finnan, S., and Oliynyk, M.
(2001). Amphotericin biosynthesis in Streptomyces nodosus:
deductions from analysis of polyketide synthase and late genes.
Chem. Biol. 8, 713–723.
25. Fjaervik, E., and Zotchev, S.B. (2005). Biosynthesis of the poly-
ene macrolide antibiotic nystatin in Streptomyces noursei.
Appl. Microbiol. Biotechnol. 67, 436–443.
26. Carmody, M., Murphy, B., Byrne, B., Power, P., Rai, D.,
Rawlings, B., and Caffrey, P. (2005). Biosynthesis of amphoter-
icin derivatives lacking exocyclic carboxyl groups. J. Biol.
Chem., in press. Published online August 3, 2005. 10.1074/
jbc.M506689200.
27. Atlas, R.M. (1993). Microbiological Media (Boca Raton, FL: CRC
Press).
28. Kieser, T., Bibb, M.J., Buttner, M.J., Chater, K.F., and
Hopwood, D.A. (2000). Practical Streptomyces Genetics
(Norwich, UK: John Innes Foundation).29. Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982). Molecular
Cloning: A Laboratory Manual (Cold Spring Harbor, NY: Cold
Spring Harbor Laboratory Press).
30. Yanisch-Perron, C., Vieira, J., and Messing, J. (1985). Improved
M13 phage cloning vectors and host strains: nucleotide sequen-
ces of the M13mp18 and pUC19 vectors. Gene 33, 103–119.
31. Larson, J.L., and Hershberger, C.L. (1986). The minimal replicon
of a streptomycete plasmid produces an ultrahigh level of plas-
mid DNA. Plasmid 15, 199–209.
32. Malpartida, F., and Hopwood, D.A. (1986). Physical and genetic
characterisation of the gene cluster for the antibiotic actinorho-
din in Streptomyces coelicolor A3(2). Mol. Gen. Genet. 205,
66–73.
